Ressources

Bienvenue dans notre banque interrogeable de ressources et de documentation sur l’approvisionnement plus sécuritaire et autres sujets connexes.

 

 

BZDs are often a difficult drug class to cease once neuroadaptation has occurred; recommendations usually involve gradual dose reductions of variable rates.

Original research | 2022
Withdrawal, Clinical guidance
Guidelines | 2022
Clinical guidance, About prescribers, Injecting drugs
Guidelines | 2020
Clinical guidance, Advocacy, Barriers and enablers, Hospitals, About prescribers
Guide or handbook | 2022
Safer supply, Clinical guidance, About prescribers
Case study | 2022
Clinical guidance, Hospitals, About prescribers, Barriers and enablers, Outcomes
Guidelines | 2021
Withdrawal, Clinical guidance, About prescribers
Guidelines | 2018
SCS/OPS, Clinical guidance, Harm reduction, Social services, Illegal drugs
Formulaire de sélection/d’évaluation | 2022
à propos des personnes qui utilisent des drogues, à propos des prescripteurs, les guides de pratique clinique, le sevrage, l'équité

The Clinical Opiate Withdrawal Scale (COWS) is a validated, clinician-administered instrument initially developed and validated for English-speaking populations.

Original research | 2022
Clinical guidance, Equity, Withdrawal, About prescribers
Guide or handbook | 2022
Substitution/OAT, Clinical guidance, Policy/Regulatory, Wrap-around services, About prescribers, Hesitancy of prescribers , Transitions in care/treatment

The “Six Moments of Infection Prevention in Injection Drug Use” provider educational tool was developed using a global, rather than pathogen-specific, infection prevention framework, highlighting t

Original research | 2022
About prescribers, Harm reduction, Clinical guidance, Safer supply, Injecting drugs
The goal of the Best Practice Recommendations is to improve the effectiveness of programs that deliver harm reduction supplies to people who use drugs and are at risk for human immunodeficiency virus
Guide or handbook | 2021
Clinical guidance, Harm reduction, Policy/Regulatory, Wrap-around services, About prescribers, Illegal drugs, Injecting drugs
Commentary | 2022
Overdose, Clinical guidance, Harm reduction, Policy/Regulatory, Hesitancy of prescribers , About prescribers, Illegal drugs, SCS/OPS
Examine the cost-effectiveness of SROM, hydromorphone, diacetylmorphine, and fentanyl in opioid use disorder, and describe the evidence-based guidelines for the use of these treatments
Lit review | 2021
Clinical guidance, Evidence base, Safer supply, About prescribers, Substitution/OAT
To present the 2021 update of the Wound Bed Preparation paradigm
Guidelines | 2021
Clinical guidance, Wrap-around services, About prescribers, Chronic pain, Injecting drugs
Guide or handbook | 2021
Overdose, Clinical guidance, Harm reduction, About prescribers, Social services, Illegal drugs, SCS/OPS
Research has shown that the vast majority of individuals who experience problems with opioid misuse and addiction have current or past experiences of trauma and violence.
Guide or handbook | 2018
Clinical guidance, Harm reduction, Sex/Gender , Mental health
Alcohol and other drug (AOD) workers from a variety of service settings are now frequently required to respond to methamphetamine users who are experiencing the harmful effects of methamphetamine, goi
Guide or handbook | 2008
Clinical guidance, Harm reduction, About prescribers, Social services, Illegal drugs, Stimulants, Transitions in care/treatment
Guidelines | 2020
Clinical guidance, Harm reduction, Safer supply, About prescribers, Substitution/OAT, Transitions in care/treatment
The aim of this work was to understand (1) the perspectives of family physicians (FPs) as it relates to opioid prescribing, and (2) the perceived barriers and enablers to guideline-adherent opioid pre
Original research | 2019
Clinical guidance, Policy/Regulatory, Hesitancy of prescribers , Safer supply, About prescribers, Barriers and enablers, Chronic pain

Affiner votre recherche

Mots clés
Format
Région